专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070225329A1 Aryl aniline beta2 adrenergic receptor agonists 有权
标题翻译：芳基苯胺β2肾上腺素受体激动剂
公开(公告)号：US20070225329A1
公开(公告)日：2007-09-27
申请号：US11805101
申请日：2007-05-22
申请人： Edmund Moran , John Jacobsen , Michael Leadbetter , Matthew Nodwell , Sean Trapp , James Aggen , Timothy Church
发明人： Edmund Moran , John Jacobsen , Michael Leadbetter , Matthew Nodwell , Sean Trapp , James Aggen , Timothy Church
IPC分类号： A61K31/47
CPC分类号： A61K31/4706 , A61K31/136 , A61K31/277 , A61K31/325 , A61K31/33 , A61K31/343 , A61K31/35 , A61K31/36 , A61K31/381 , A61K31/385 , A61K31/405 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/47 , A61K31/4704 , A61K31/4709 , A61K31/58 , C07C213/04 , C07C215/34 , C07C215/60 , C07C217/84 , C07C229/38 , C07C233/43 , C07C317/36 , C07D213/75 , C07D215/227 , C07D215/26 , C07D231/22 , C07D239/38 , C07D239/42 , C07D239/47 , C07D239/69 , C07D277/46 , C07D311/80 , C07D321/10 , C07D401/12 , C07D409/12 , C07D413/12 , A61K2300/00
摘要： The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
摘要翻译：本发明提供新的β2肾上腺素能受体激动剂式（I）化合物：其中R 1 -R 13和w具有任何值在说明书中描述。本发明还提供了这些化合物和其它治疗剂的组合，包含这些化合物和组合的药物组合物，使用这些化合物治疗与β2肾上腺素能受体活性有关的疾病的方法，以及可用于制备此类化合物。

2. 发明申请

US20060178410A1 Aryl aniline beta2 adrenergic receptor agonists 有权
标题翻译：芳基苯胺β2肾上腺素受体激动剂
公开(公告)号：US20060178410A1
公开(公告)日：2006-08-10
申请号：US11400959
申请日：2006-04-10
申请人： Edmund Moran , John Jacobsen , Michael Leadbetter , James Aggen , Timothy Church
发明人： Edmund Moran , John Jacobsen , Michael Leadbetter , James Aggen , Timothy Church
IPC分类号： C07D213/26 , A61K31/44 , A61K31/40 , A61K31/138
CPC分类号： C07D213/75 , C07C215/60 , C07C217/84 , C07C229/38 , C07C233/43 , C07C317/36 , C07D213/76 , C07D215/227 , C07D215/26 , C07D231/22 , C07D239/38 , C07D239/42 , C07D239/47 , C07D277/46 , C07D277/52 , C07D295/26 , C07D311/80 , C07D319/18 , C07D321/10 , C07D401/12 , C07D409/12 , C07D413/12
摘要： The invention provides novel β2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with β2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
摘要翻译：本发明提供新的β2肾上腺素能受体激动剂式（I）化合物：其中R 1 -R 13和w具有任何值在说明书中描述。本发明还提供包含这些化合物的药物组合物，使用这些化合物治疗与β2肾上腺素能受体活性相关的疾病的方法，以及可用于制备这些化合物的方法和中间体。

3. 发明申请

US20070298112A1 Crystalline forms of a biphenyl compound 有权
标题翻译：联苯化合物的结晶形式
公开(公告)号：US20070298112A1
公开(公告)日：2007-12-27
申请号：US11890880
申请日：2007-08-08
申请人： Sabine Axt , Timothy Church , Viengkham Malathong
发明人： Sabine Axt , Timothy Church , Viengkham Malathong
IPC分类号： A61K31/4545 , A61K31/58 , A61K9/14 , A61M11/00 , A61M15/00
CPC分类号： C07D401/12 , A61K9/0073 , A61K9/14 , A61K9/19 , A61K31/4545 , A61K31/56 , A61K31/58 , A61K45/00 , A61K45/06 , A61M15/00 , A61M2202/064 , C07B2200/13 , C07D211/62 , C07D211/94
摘要： The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.
摘要翻译：本发明提供联苯-2-基氨基甲酸1-（2 - {[4-（4-氨基甲酰基哌啶-1-基甲基）苯甲酰基]甲基氨基}乙基）哌啶-4-基酯的结晶形式及其药学上可接受的溶剂合物。结晶形式可以是游离碱，或盐，例如二磷酸盐，单硫酸盐或二恶烷酸盐。本发明还提供包含这些结晶化合物或使用这些化合物制备的药物组合物; 制备结晶化合物的方法和中间体; 以及使用这些化合物治疗肺部疾病的方法。

4. 发明申请

US20070112027A1 Crystalline forms of a biphenyl compound 审中-公开
公开(公告)号：US20070112027A1
公开(公告)日：2007-05-17
申请号：US11371445
申请日：2006-03-09
申请人： Sabine Axt , Timothy Church , Viengkham Malathong
发明人： Sabine Axt , Timothy Church , Viengkham Malathong
IPC分类号： C07D401/02 , A61K31/4545
CPC分类号： C07D401/12 , A61K9/0073 , A61K9/14 , A61K9/19 , A61K31/4545 , A61K31/56 , A61K31/58 , A61K45/00 , A61K45/06 , A61M15/00 , A61M2202/064 , C07B2200/13 , C07D211/62 , C07D211/94
摘要： The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and intermediates for preparing the crystalline compounds; and methods of using these compounds to treat a pulmonary disorder.

5. 发明申请

US20050054117A1 Macrophage migration inhibitory factor as a marker for cardiovascular risk 失效
标题翻译：巨噬细胞迁移抑制因子作为心血管风险的标志物
公开(公告)号：US20050054117A1
公开(公告)日：2005-03-10
申请号：US10660301
申请日：2003-09-10
申请人： Brett Giroir , Monty Willis , Timothy Church
发明人： Brett Giroir , Monty Willis , Timothy Church
IPC分类号： G01N33/68 , G01N33/543
CPC分类号： G01N33/6893 , G01N2800/32
摘要： Macrophage migration inhibitory factor (MIF) is a clinically useful biochemical marker of cardiovascular risk. Risk assessment includes the step of detecting in the blood of a person MIF concentration as a marker of cardiovascular risk for the person. The method may further comprise the step of assigning to the person a cardiovascular risk metric proportional to the MIF concentration, and/or prescribing for the person a cardiovascular treatment modality in accordance with the MIF concentration. The method is useful as a primary screen, and may be used in conjunction with or as a substitute for additional tests, such as a stress test, CRP assay, LDL assay, etc. The detecting step may be repeated over time intervals and/or treatment to monitor change in cardiovascular risk for the person over time and/or treatment.
摘要翻译：巨噬细胞迁移抑制因子（MIF）是临床上有用的心血管风险生化标志物。风险评估包括检测人血液中MIF浓度作为人心血管风险的标志物的步骤。该方法可以进一步包括向人们分配与MIF浓度成比例的心血管风险度量，和/或根据MIF浓度向患者分配心血管治疗方式的步骤。该方法可用作主要屏幕，并且可以与附加测试结合使用或代替其他测试，例如压力测试，CRP测定，LDL测定等。检测步骤可以随时间间隔和/或治疗以监测随时间和/或治疗的人的心血管风险变化。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式